Thought Leadership

Reliability and impact of drug authentication at the point of dispensing
This report, written by the Prof Steven Simoens of the Katholieke Universiteit Leuven, documents the findings from an independent audit of Aegate's drug authentication service.

To download a copy of the summary click here
If you would like to see the full report - please email leanne.huff@aegate.com

---

Working Together on Mass Serialisation: Whose Responsibility is Ensuring Patient Safety
This report, written by Frost & Sullivan and commissioned by Aegate, reviews the steps that have been taken to try and address this burgeoning issue both from a national legislative level and via the use of new technologies.

To download a copy of the executive summary click here
If you would like to see the full report - please email leanne.huff@aegate.com

---

Movers & Shakers interview
An interview with Gary Noon, CEO of Aegate, on the need for mass serialisation as the key driver to enhance patient safety:

Full inteview available at the following link:
http://www.frost.com/prod/servlet/exec-brief-movers-feature.pag?sid=140061509

---

Verily Validated (Appeared in PMPS in Winter 2008 issue)
The number of drug recalls, substandard medicines and counterfeit products continues to increase. In the UK alone there have been over 20 product recalls since Jan 2007 with The World Health Organization (WHO) believing up to10% of the world's drug supply may be counterfeit. As a result, now more than ever, the pharmaceutical sector is facing significant challenges in the area of patient safety. Recognizing this need, validation through authentication at the point of dispensing, is already being deployed by pharmacies throughout Europe with co-operation from some of the biggest pharmaceutical companies...

Full article available at the following link: http://www.samedanltd.com/magazine/15/issue/92/article/2059

---

Playing Safe with Patient Safety (Appeared in PMPS Autumn 2007 issue)
The pharmaceutical supply chain is complex and provides numerous opportunities for the unscrupulous to interfere with drugs. In Europe today, with EU legislation that encourages the free movement of goods, and coupled by price differentials between countries, trading in pharmaceuticals is widespread and lucrative/ Companies and regulators have common goals: to ensure the integrity of the supply chain, prevent counterfeiting, and respond rapidly if a problem occurs (in other words, withdrawing a product from the market should a recall be necessary.) However, at the moment, there is no common approach to these goals. There is growing complexity, confusion and fragmentation within the industry...

Full article available at the following link: http://www.samedanltd.com/magazine/15/issue/86/article/1973